American Journal of Cardiovascular Drugs

, Volume 7, Issue 5, pp 373–380 | Cite as

Effects of ACE Inhibitors or ↓-Blockers in Patients Treated with the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine in the African-American Heart Failure Trial

  • Jalal K. Ghali
  • S. William Tam
  • Keith C. Ferdinand
  • JoAnn Lindenfeld
  • Michael L. Sabolinski
  • Anne L. Taylor
  • Manuel Worcel
  • Charles L. Curry
  • Jay N. Cohn
  • A-HeFT Investigators
Original Research Article



In the A-HeFT (African-American Heart Failure Trial), treatment of African-American patients with New York Heart Association (NYHA) class III/IV heart failure (HF) with fixed-dose combination (FDC) of isosorbide dinitrate/hydralazine (I/H) reduced mortality and morbidity and improved patient reported functional status compared with standard therapy alone.


To examine the benefit of FDC I/H in subgroups based on baseline drug therapy and to investigate whether ACE inhibitors and/or angiotensin receptor antagonists (angiotensin receptor blockers) [ARBs] or ↓-adrenoceptor antagonists (↓-blockers) provided additional benefit in FDC I/H-treated African-American patients with HF.

Study design

The A-HeFT was a double-blind, placebo-controlled study enrolling 1050 patients stabilized on optimal HF therapies and with NYHA class III/IV HF with systolic dysfunction conducted during the years 2001–4 with up to 18 months follow-up. The primary endpoint was a composite of mortality, first HF hospitalization, and improvement of quality of life at 6 months. Secondary endpoints included mortality, hospitalizations, and change in quality of life. Prospective Kaplan-Meier survival analyses were used for differences between FDC I/H and placebo groups and retrospective analyses were conducted within FDC I/H-treated and placebo groups.


Subgroup analysis for mortality, event-free survival (death or first HF hospitalization), and HF hospitalization showed that FDC I/H, compared with placebo, was effective with or without ACE inhibitors or ↓-blockers or other standard medications with all-point estimates favoring the FDC I/H group. Within the placebo-treated group, ↓-blockers or ACE inhibitors and/or ARBs were efficacious in improving survival (hazard ratio [HR] 0.33; p < 0.0001 for ↓-blocker use and HR 0.39; p = 0.01 for ACE inhibitor and/or ARB use). However, within the FDC I/H-treated group, use of ↓-blockers, but not ACE inhibitors and/or ARBs, provided additional significant benefit for survival (HR 0.44; p = 0.029 and HR 0.60; p = 0.34, respectively), event-free survival (HR 0.62; p = 0.034 and HR 0.72; p = 0.29, respectively) and the composite score of death, HF hospitalization and change in quality of life (p = 0.016 and p = 0.13, respectively).


Based on the analysis of baseline medication use in the A-HeFT, FDC I/H was superior to placebo with or without ↓-blockers or ACE inhibitor. However, ↓-blockers but not ACE inhibitors and/or ARBs provided additional significant benefit in African-Americans with HF treated with FDC I/H. These analyses are hypotheses generating and their confirmation in clinical trials needs to be considered.


  1. 1.
    Taylor AL, Ziesche S. Yancy C, et al., for the African American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049–57.PubMedCrossRefGoogle Scholar
  2. 2.
    Taylor AL, Ziesche S, Yancy CW, et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation 2007; 115: 1747–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Angus DC, Linde-Zwirble WT, Tam SW, et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation 2005; 112: 3745–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in blacks as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344: 1351–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Carson P, Ziesche W, Johnson G, et al., for the Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trial. J Card Fail 1999; 5 178–87.PubMedCrossRefGoogle Scholar
  6. 6.
    Alderman MH, Cohen HW, Sealey JE, et al. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17: 1–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Brewster LM, van Montfrans GA, Kleijnen J. Scientific review: antihypertensive drug therapy in black patients. Ann Intern Med 2004; 141: 614–27.PubMedGoogle Scholar
  8. 8.
    Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension 2004; 43: 566–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Bassett Jr DR, Duey WJ, Walker AJ, et al. Racial differences in maximal vasodilatory capacity of forearm resistance vessels in normotensive young adults. Am J Hypertens 1992; 5: 781–6.PubMedGoogle Scholar
  10. 10.
    Stein CM, Lanf CC, Nelson R, et al. Vasodilation in black Americans: attenuated nitric-oxide mediated responses. Clin Pharmacol Ther 1997; 62: 436–43.PubMedCrossRefGoogle Scholar
  11. 11.
    Cardillo C, Kilcoyne CM, Cannon III RO, et al. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension 1998; 31: 1235–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Cardillo C, Kilcoyne CM, Cannon III RO, et al. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation 1999; 99: 90–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Stein CM, Lang CC, Nelson R, et al. Increased vascular adrenergic vasoconstriction and decreased vasodilation in blacks: additive mechanisms leading to enhanced vascular reactivity. Hypertension 2000; 36: 945–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Campia U, Choucair WK, Bryant MB, et al. Reduced endothelium-dependent and independent dilation of conductance arteries in African Americans. J Am Coll Cardiol 2002; 40: 754–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Li R, Lyn D, Lapu-Bula R, et al. Relaxation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function and blood pressure in African Americans. Am J Hypertens 2004; 17: 560–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Houghton JL, Philbin EF, Strogatz DS, et al. The presence of African American race predicts improvement of coronary endothelial function after supplementary L-arginine. J Am Coll Cardiol 2002; 39: 1314–22.PubMedCrossRefGoogle Scholar
  17. 17.
    Kahn DF, Duffy SJ, Tomasian D, et al. Effects of Black race one forearm resistance vessel function. Hypertension 2002; 40: 195–201.PubMedCrossRefGoogle Scholar
  18. 18.
    Androne AS, Hryniewicz K, Hudaihed A, et al. Comparison of metabolic vasodilation in response to exercise and ischemia and endothelium dependent flow-mediated dilation in African American versus non-African American patients with chronic heart failure. Am J Cardiol 2006; 97: 685–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult [online]. Available from URL: [Accessed 2007 Aug 16].
  20. 20.
    Dries DL, Strong MH, Cooper RS, et al. Efficacy of angio-tensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002; 40: 311–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Ghali JK. Race, ethnicity, and heart failure. J Card Fail 2002; 6: 387–9.CrossRefGoogle Scholar
  22. 22.
    Yancy CW, Foweler MB, Colucci WS, et al., For the U.S. Carvedilol Heart Failure Study Group: race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001; 344: 1358–65.PubMedCrossRefGoogle Scholar
  23. 23.
    Goldstein S, Deedwania P, Gottlieb S, et al., on behalf of the MERIT-HF Study Group. Metoprolol CR/XL in black patients with heart failure (from the metoprolol CR/XL randomized intervention trial in chronic heart failure). Am J Cardiol 2003; 92: 478–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Ghali JK. Beta-blockers in selected heart failure populations. Curr Heart Fail Rep 2005; 2: 100–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Liu YH, Xu J, Yang XP, et al. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension 2002; 39: 375–81.PubMedCrossRefGoogle Scholar
  26. 26.
    García-Estaň J, Ortiz MC, O’Valle F, et al. Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats. Clin Sci 2006; 110: 227–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Fujii S, Suzuki Y, Yoshimura T, et al. In vivo three-dimensional EPR imaging of nitric oxide production from isosorbide dinitrate in mice. Am J Physiol 1998; 274: G857–62.PubMedGoogle Scholar
  28. 28.
    Münzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest 1996; 98: 1465–70.PubMedCrossRefGoogle Scholar
  29. 29.
    Dries DL, Exner DV, Gersch BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999; 340: 609–16.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Jalal K. Ghali
    • 1
  • S. William Tam
    • 2
  • Keith C. Ferdinand
    • 3
  • JoAnn Lindenfeld
    • 4
  • Michael L. Sabolinski
    • 2
  • Anne L. Taylor
    • 5
  • Manuel Worcel
    • 2
  • Charles L. Curry
    • 6
  • Jay N. Cohn
    • 5
  • A-HeFT Investigators
  1. 1.University Health Center, 2E, Wayne State UniversityDetroitUSA
  2. 2.NitroMed, Inc.LexingtonUSA
  3. 3.Black Cardiologist AssociationAtlantaUSA
  4. 4.University Hospital, University of ColoradoDenverUSA
  5. 5.Cardiovascular Division, Department of MedicineUniversity of MinnesotaMinneapolisUSA
  6. 6.Howard University, College of MedicineUSA

Personalised recommendations